A pilot study of an anti-MRSA bio-engineered lacteal complex (anti-MRSA BLC) in a murine septicemia model

Jesse A. Stoff, David E. Nix, D. W. DeYoung

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen of humans and other animals, causing septicemia, abcessation, toxemia, and other infectious diseases. Refined bioengineered lacteal complex (BLC), made specifically against MRSA, is a novel complex of low molecular weight immunogenic and antimicrobial molecules. It was evaluated in vivo using a mouse model of MRSA-induced peritonitis. Intraperitoneal dosing of anti-MRSA BLC demonstrated a therapeutic effect (83% survival) against an intraperitoneal MRSA challenge that caused 100% mortality in untreated animals. Anti-MRSA BLC is a promising therapeutic modality for MRSA infection.

Original languageEnglish (US)
Pages (from-to)601-607
Number of pages7
JournalImmunopharmacology and Immunotoxicology
Volume28
Issue number4
DOIs
StatePublished - Oct 1 2006

Keywords

  • Bio-engineered Lacteal Complex (BLC)
  • Methicillin-Resistant Staphylococcus Aureus (MRSA)
  • Murine Peritonitis
  • Sepsis
  • Toxemia

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Toxicology
  • Pharmacology

Fingerprint Dive into the research topics of 'A pilot study of an anti-MRSA bio-engineered lacteal complex (anti-MRSA BLC) in a murine septicemia model'. Together they form a unique fingerprint.

  • Cite this